Commentary|Articles|June 17, 2026

ADA 2026: Key Pharmacotherapy Advances in Type 1 and Type 2 Diabetes

Author(s)Jennifer Goldman, PharmD, RPh, CDCES, BC-ADM, FCCP

Fact checked by: Gillian McGovern, Editor, Ron Panarotti

The ADA Scientific Sessions highlighted important advances across the diabetes treatment landscape.

The 86th American Diabetes Association (ADA) Scientific Sessions, held June 5 through 8, 2026, in New Orleans, Louisiana, highlighted important advances across the diabetes treatment landscape. Although obesity therapeutics and diabetes technology generated considerable attention, several presentations focused specifically on therapies for type 1 diabetes (T1D) and type 2 diabetes (T2D).